Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Fabrizio Biundo
Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Gabriel G.L. Shlager
Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Eun S. Park
Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Ping Wang
Department of Genetics, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Maria E. Gulinello
Behavioral Core Facility, Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Şölen Gokhan
Institute for Brain Disorders and Neural Regeneration, Departments of Neurology, Neuroscience, and Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Harmony C. Ketchum
Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Kusumika Saha
Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Michael A. DeTure
Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
Dennis W. Dickson
Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA
Zbignew K. Wszolek
Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA
Deyou Zheng
The Saul R. Korey Department of Neurology, Dominick P. Purpura Department of Neuroscience, and Department of Genetics, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Institute of Experimental Immunology, University of Zurich, Zurich 8057, Switzerland
Daqian Sun
Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
Mark F. Mehler
Institute for Brain Disorders and Neural Regeneration, Departments of Neurology, Neuroscience, and Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, NY 10461, USA
E. Richard Stanley
Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Corresponding author
Summary: CSF-1R haploinsufficiency causes adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). Previous studies in the Csf1r+/− mouse model of ALSP hypothesized a central role of elevated cerebral Csf2 expression. Here, we show that monoallelic deletion of Csf2 rescues most behavioral deficits and histopathological changes in Csf1r+/− mice by preventing microgliosis and eliminating most microglial transcriptomic alterations, including those indicative of oxidative stress and demyelination. We also show elevation of Csf2 transcripts and of several CSF-2 downstream targets in the brains of ALSP patients, demonstrating that the mechanisms identified in the mouse model are functional in humans. Our data provide insights into the mechanisms underlying ALSP. Because increased CSF2 levels and decreased microglial Csf1r expression have also been reported in Alzheimer’s disease and multiple sclerosis, we suggest that the unbalanced CSF-1R/CSF-2 signaling we describe in the present study may contribute to the pathogenesis of other neurodegenerative conditions. : ALSP is a dementia caused by dominantly inherited inactivating mutations in the CSF1R. Chitu et al. report that CSF2 expression is increased in ALSP patients. Targeting Csf2 in ALSP mice prevents behavioral deficits and callosal atrophy and reduces demyelination by normalizing microglial function, identifying CSF-2 as a potential therapeutic target in ALSP. Keywords: ALSP, CSF-1R, GM-CSF, microglia, leukodystrophy, demyelination, neurodegeneration